Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Inclusion Criteria: Metastatic Prostate Cancer Patients: * Adult male ≥ 18 years of age * Patients with histologically confirmed prostate cancer at MSKCC * Progressive disease manifest by either: * Imaging modalities: * Bone Scan: New osseous lesions on bone scan and/or * MRI or CT: An increase in measurable soft tissue disease or the appearance of new sites of disease. OR * Biochemical progression: At least 3 rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements obtained 2 or more weeks apart. The increase over the range of values should be at least 25%. * Visible lesions by CT, bone scan, or MRI that are consistent with disease * Performance status of 60 or higher (Karnofsky scale) (Appendix B) * Ability to understand and willingness to sign a written informed consent document Rising PSA Prostate Cancer Patients: * Adult male ≥18 years of age * Patients with histologically confirmed prostate cancer at MSKCC * Undergone radical prostatectomy * Detectable PSA (\>0.05 ng/mL) that rises on subsequent evaluation * Radiographic evaluation involving bone imaging and cross sectional imaging of at least the pelvis that is negative or equivocal for metastatic disease * Performance status of 60 or higher (Karnofsky scale) (Appendix B) * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Patients meeting any of the following criteria will not be eligible for study entry (Metastatic and Rising PSA cohorts): * Previous anaphylactic reaction to either J591 or FDG * Hepatic laboratory values * Bilirubin \> 1.5 x ULN (institutional upper limits of normal) Exception: patient's with a history of Gilbert's disease * AST/ALT \> 2.5 x ULN * Albumin \< 2 g/dL